ENDRA Life Sciences (NDRA) Competitors $3.58 +0.08 (+2.29%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$3.56 -0.02 (-0.56%) As of 06/27/2025 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock NDRA vs. NURO, IINN, CODX, SINT, POAI, TNON, STRR, BLAC, QNRX, and CHEKShould you be buying ENDRA Life Sciences stock or one of its competitors? The main competitors of ENDRA Life Sciences include NeuroMetrix (NURO), Inspira Technologies OXY B.H.N. (IINN), Co-Diagnostics (CODX), Sintx Technologies (SINT), Predictive Oncology (POAI), Tenon Medical (TNON), Star Equity (STRR), Bellevue Life Sciences Acquisition (BLAC), Quoin Pharmaceuticals (QNRX), and Check-Cap (CHEK). These companies are all part of the "medical equipment" industry. ENDRA Life Sciences vs. Its Competitors NeuroMetrix Inspira Technologies OXY B.H.N. Co-Diagnostics Sintx Technologies Predictive Oncology Tenon Medical Star Equity Bellevue Life Sciences Acquisition Quoin Pharmaceuticals Check-Cap NeuroMetrix (NASDAQ:NURO) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation. Does the media prefer NURO or NDRA? In the previous week, ENDRA Life Sciences had 2 more articles in the media than NeuroMetrix. MarketBeat recorded 2 mentions for ENDRA Life Sciences and 0 mentions for NeuroMetrix. ENDRA Life Sciences' average media sentiment score of 0.94 beat NeuroMetrix's score of 0.00 indicating that ENDRA Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment NeuroMetrix Neutral ENDRA Life Sciences Positive Is NURO or NDRA more profitable? ENDRA Life Sciences has a net margin of 0.00% compared to NeuroMetrix's net margin of -203.71%. NeuroMetrix's return on equity of -42.56% beat ENDRA Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets NeuroMetrix-203.71% -42.56% -39.26% ENDRA Life Sciences N/A -140.96%-106.14% Which has more risk & volatility, NURO or NDRA? NeuroMetrix has a beta of 1.82, suggesting that its stock price is 82% more volatile than the S&P 500. Comparatively, ENDRA Life Sciences has a beta of -0.21, suggesting that its stock price is 121% less volatile than the S&P 500. Do analysts rate NURO or NDRA? ENDRA Life Sciences has a consensus target price of $50.00, indicating a potential upside of 1,296.65%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe ENDRA Life Sciences is more favorable than NeuroMetrix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroMetrix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00ENDRA Life Sciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in NURO or NDRA? 19.4% of NeuroMetrix shares are held by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are held by institutional investors. 7.3% of NeuroMetrix shares are held by company insiders. Comparatively, 0.0% of ENDRA Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has stronger earnings and valuation, NURO or NDRA? NeuroMetrix has higher revenue and earnings than ENDRA Life Sciences. NeuroMetrix is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeuroMetrix$3.03M3.09-$6.53M-$4.59-0.99ENDRA Life SciencesN/AN/A-$11.51M-$172.04-0.02 SummaryNeuroMetrix beats ENDRA Life Sciences on 8 of the 15 factors compared between the two stocks. Get ENDRA Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NDRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NDRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NDRA vs. The Competition Export to ExcelMetricENDRA Life SciencesMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.64M$6.81B$5.47B$8.93BDividend YieldN/A1.04%5.32%4.14%P/E Ratio-0.0226.5826.2119.67Price / SalesN/A80.56387.56105.07Price / CashN/A21.0136.4056.84Price / Book0.754.737.875.43Net Income-$11.51M$171.62M$3.16B$249.20M7 Day Performance12.23%2.79%3.10%3.99%1 Month Performance10.84%-0.97%4.62%4.82%1 Year Performance-99.96%20.31%31.74%17.00% ENDRA Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NDRAENDRA Life Sciences3.1437 of 5 stars$3.58+2.3%$50.00+1,296.6%-100.0%$2.64MN/A-0.0220NURONeuroMetrixN/A$4.55+4.4%N/A+23.3%$9.37M$3.03M-0.9920High Trading VolumeIINNInspira Technologies OXY B.H.N.3.051 of 5 stars$0.76+3.9%$2.00+162.8%-38.4%$9.25MN/A0.0020News CoverageAnalyst UpgradeCODXCo-Diagnostics4.4819 of 5 stars$0.26-2.5%$5.50+2,055.2%-79.0%$8.79M$3.91M-0.22100News CoverageSINTSintx Technologies2.5505 of 5 stars$3.07-2.5%$28.00+812.1%-32.9%$7.90M$2.89M-0.0640News CoveragePOAIPredictive Oncology2.4753 of 5 stars$0.86-1.7%$3.00+250.6%-20.2%$7.77M$1.62M-0.2830TNONTenon Medical2.1016 of 5 stars$0.89-1.7%$4.67+425.6%+55.7%$6.86M$3.28M-0.038STRRStar Equity3.6446 of 5 stars$1.96-1.5%$5.00+155.1%-55.5%$6.39M$53.36M-0.57460Gap DownBLACBellevue Life Sciences AcquisitionN/A$1.54-4.9%N/A-87.5%$6.22MN/A0.00N/ANews CoverageHigh Trading VolumeQNRXQuoin Pharmaceuticals0.9176 of 5 stars$8.58-1.4%N/A-54.5%$5.12MN/A-0.184News CoverageGap DownCHEKCheck-Cap1.2957 of 5 stars$0.75+1.6%N/A-61.4%$4.32MN/A-0.2580 Related Companies and Tools Related Companies NeuroMetrix Competitors Inspira Technologies OXY B.H.N. Competitors Co-Diagnostics Competitors Sintx Technologies Competitors Predictive Oncology Competitors Tenon Medical Competitors Star Equity Competitors Bellevue Life Sciences Acquisition Competitors Quoin Pharmaceuticals Competitors Check-Cap Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NDRA) was last updated on 6/29/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ENDRA Life Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ENDRA Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
